Background: There is no widely accepted standard medical treatment for apocrine gland anal sac adenocarcinoma (AGASACA) in dogs. Targeted agents such as toceranib may be effective in treatment of AGASACA, but the number of clinical reports investigating its efficacy is limited.
occurs before distant metastasis to sites such as the lungs, liver, and spleen. 3 Polyuria and polydipsia may be present as a consequence of paraneoplastic hypercalcemia, which is reported in approximately 25% to 50% of cases. 3, 5, 6 Despite its high propensity to metastasize, this tumor tends to have an overall indolent disease course with median survival times of 1-2 years with single or multimodal therapeutic modalities, including surgery, 6, 7 chemotherapy, 8, 9 and radiation. 5 Although numerous chemotherapeutic agents (carboplatin, 8 actinomycin D, 9 mioxantrone, 5 and melphalan 6 ) have been investigated, the definitive role of adjuvant chemotherapy in the treatment of AGASACA remains unclear. Alternative treatment options such as targeted therapy also require further assessment to define therapeutic benefit.
Toceranib phosphate (Palladia) is a small molecule tyrosine kinase inhibitor approved by the United States Food and Drug Administration (FDA) for the treatment of high-grade cutaneous mast cell tumors in dogs. 10 Toceranib has activity against several members of the splitkinase family including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), Kit and Flt-3. 11, 12 Toceranib's mechanism of action results from competitive blockade of the ATP-binding site of tyrosine kinase receptors, impairing phosphorylation and downstream signaling. 13 With both antiangiogenic as well as antitumor effects, toceranib has potential therapeutic activity in a wide range of tumor types in dogs. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] A phase I clinical trial and retrospective case series suggest that toceranib exhibits potential clinical antitumor activity against mixed mammary carcinoma, soft tissue sarcoma, multiple myeloma, AGASACA, osteosarcoma, thyroid carcinoma, head and neck carcinoma, and nasal carcinoma. 12, 24 Use of toceranib for treatment of AGASACA has been evaluated in a limited number of studies. In 1 study of 32 dogs with AGASACA, a clinical benefit from toceranib was reported in 87.5% of dogs, with 25% achieving partial response (PR) and 75% experiencing stable disease (SD). 24 The median duration for PR was 22 weeks and the median duration for SD was 30.5 weeks. A more recent retrospective study evaluated dogs diagnosed with stage 4 AGASACA, and 13 of 15 dogs experienced clinical benefit from toceranib treatment by stabilization of their disease. 25 Thus, toceranib may provide an attractive adjunctive treatment option for AGASACA in dogs, and further investigation of its effectiveness is needed.
Our primary aim was to retrospectively evaluate the efficacy of adjuvant and primary toceranib treatment in dogs with AGASACA. A secondary aim was to identify prognostic factors in the study population. A clinical benefit was defined as complete response (CR) or PR at any point in time or SD for at least 10 weeks. We hypothesized that toceranib would provide clinical benefit in dogs treated for AGASACA. Inclusion criteria   included either a cytologic or histologic diagnosis of AGASACA for   which toceranib was used as either sole, adjuvant, or neoadjuvant   treatment. All patients underwent complete staging including history,   physical examination, CBC, serum biochemistry profile, urinalysis,   3-view thoracic radiographs, and abdominal ultrasound or abdominal computerized tomography (CT) scanning. Dogs that had been treated by surgery or nonconcurrent chemotherapy in addition to toceranib also were included in the study. Dogs treated by radiation therapy were excluded.
| MATERIALS AND METHODS

| Case selection and data collection
Restaging by physical examination, thoracic radiographs, and abdominal ultrasound examination was recommended every 2 to 3 months to assess therapeutic response. A CBC was recommended 2 weeks after initiating toceranib to monitor for myelosuppression.
Reevaluations including physical examination, CBC, serum biochemistry profile, urinalysis, urine protein-to-creatinine ratio (UPC; if indicated), blood pressure measurement, thoracic radiographs and abdominal ultrasound or CT scan of the thorax and abdomen were recommended 1 month after starting toceranib. If toceranib was well tolerated, reevaluations with restaging were recommended every 2 to 3 months while receiving continued treatment. The majority of patients (26/36) were restaged according to these guidelines. A minority of the study population (10/36) was not consistently restaged because of lack of client compliance. All dogs were included on an intent-to-treat basis. The standard toceranib (Palladia, Zoetis, 
| Assessment of adverse events (AEs)
All patients were evaluated at the UWVC before toceranib treatment. Physical examination, CBC, serum biochemistry profile, urinalysis, and blood pressure measurement were recommended before treatment, 1 month after initiation of toceranib treatment and every 2 to 3 months while receiving toceranib. Urine protein-to-creatinine ratio was performed if results of a patient's urinalysis or blood pressure measurement indicated proteinuria or systemic hypertension. All AEs were graded according to the Veterinary Co-operative Oncology Group's common terminology criteria for AEs (VCOG-CTCAE v1.1). 27 For gastrointestinal AEs, supportive care included, but was not limited to, a 7-day toceranib treatment holiday, antidiarrheal agents (eg, metronidazole, tylosin), antiemetics (eg, maropitant, metoclopramide, ondansetron) and gastric protectants (eg, omeprazole, famotidine).
Treatment of hypertension included an angiotensin-converting enzyme
(ACE) inhibitor (eg, enalapril, benazepril), amlodipine, or both.
| Statistical analysis
Descriptive statistics were used to summarize the variables collected on the group of patients treated and to define toceranib dosing strata.
The Kaplan-Meier (KM) product of survival probabilities was used to assess PFS and OST curves for the population and for different cohorts of interest. Dogs lost to follow-up were censored in the survival analysis at the last known follow-up event. Survival curves were compared using the log rank test. A multivariable Cox proportional hazard model was used to assess the rate of possible death events given the prognostic factors. A P-value for the log rank test of <.05 was considered statistically significant. All analyses were performed in R, 28 and the KM curves and Cox proportional hazard models were performed using the survival package (GraphPad Software, La Jolla, California). 29 3 | RESULTS
| Study population
Thirty-six dogs diagnosed with AGASACA and treated with toceranib alone or in combination with surgery, nonconcurrent chemotherapy or both during the study's time period fulfilled the study's inclusion criteria. The population consisted of 11 female dogs and 25 male dogs, and all dogs were either spayed or neutered. Nineteen different breeds were represented (Table 1) Table 2 .
| Treatments
The majority of dogs (23/36, 63.9%) underwent surgery for removal of the primary tumor before treatment with toceranib. Regional 
| Treatment outcomes
Toceranib-associated median OST and the median OST from the time of diagnosis (36 dogs) were 434 days ( Figure 1A ) and 827 days ( Figure 1B) , respectively. The PFS (from initiation of toceranib treatment) in the study population was 313 days ( Figure 1C ). Among S1 and S2) . Median PFS and OST for each cohort are listed in Table 4 . (Table 4 ).
| Prognostic factors
| DISCUSSION
Our primary objective was to assess the efficacy of toceranib in dogs with AGASACA. The demographics of our study population were consistent with previous reports, providing support for an accurate representation of dogs with AGASACA. [1] [2] [3] [4] [5] 30 Most dogs treated in the macroscopic disease setting (69%) experienced clinical benefit from treatment (20.7%, PR; 48.3%, SD) and clinical benefit was positively associated with OST and PFS. These response outcomes are consistent with previous reports. 24, 25 Our study further supports use of toceranib in this therapeutic setting.
Toceranib treatment-associated median OST and PFS were 434 days and 313 days, respectively ( Figure 1A and 1C ). Half of the study population (50%) received chemotherapy before salvage toceranib treatment, often after having failed several chemotherapy protocols. The general OST for dogs treated with toceranib and chemotherapy (before or after toceranib treatment) is impacted by all treatment modalities and not just toceranib. Therefore, a direct comparison of PFS (after initiation of toceranib) with PFS of other agents used for first-line adjuvant therapy is not necessarily a valid comparison. Similarly, toceranib treatment associated-OST (defined from the time of initiation of toceranib treatment) in our study population is not directly comparable to other studies that calculated OST from the initial treatment or disease diagnosis. Thus, we also calculated OST from the time of diagnosis, which was 827 days ( Figure 1B ). This outcome is more consistent with the previously reported survival times, ranging from 16 to 31 months. [4] [5] [6] 30 The rate of metastatic disease in our study population (86.1%) was consistent with that of previous reports, but skewed toward the higher end of the range. Again, the majority of dogs in our study were evaluated later in the course of their disease, because toceranib often was used as adjuvant treatment after surgery or salvage treatment after failure of cytotoxic chemotherapy. Therefore, this higher rate of metastasis is likely a result of selection bias. It is also possible that the toceranib-associated survival time (434 days) in our study was falsely decreased because of selection bias and the advanced extent of disease in most patients.
A secondary aim of our study was to identify prognostic factors in the study population. Multivariate subgroup analysis, however, can be subject to bias and statistical concerns when used in small cohorts and in retrospective analysis. 31 Our multivariate Cox hazard analysis suggests that clinical benefit from toceranib treatment was a positive prognostic factor for clinical outcome, but toceranib dosage was not found to be prognostic ( Table 4 ). The original label dosage for toceranib was 3.25 mg/kg q48h, which was first established in the phase I clinical trial to determine the maximum tolerated dose (MTD). 12 Several more recent reports show that dosages of toceranib ranging from 2.4 to 2.9 mg/kg q48h provide exposure considered sufficient for target inhibition. 12, 24, 32 The lower dosage of toceranib, although still effective, also may have fewer AEs, which is advantageous. In our study, no significant difference was found in PFS or OST among toceranib dosage groups. Therefore, our results further support a lower than MTD toceranib dosing protocol for treating dogs with substantial AE profiles.
Based on the multivariable Cox hazard model, toceranib treatment in the microscopic disease setting was associated with prolonged PFS but not with OST (Table 4 ). Prolonged survival in dogs that had surgical treatment of AGASACA has been well documented in the veterinary literature. 6, 7, [33] [34] [35] Furthermore, positive outcomes have been reported in dogs treated surgically, even in cases of metastatic disease. 30, 35 In our study, only 7 dogs were treated in the microscopic disease setting. The small sample size and difficulty of true assessment of response in the microscopic disease setting restricted interpretation of our data, and therefore these findings should not be used to contradict the current gold standard treatment approach of aggressive surgical treatment, even in face of regional or distant metastasis. Surgical extirpation of metastatic lymph nodes should still be considered in patients that develop progressive metastatic disease later in their clinical course.
Hypercalcemia also was found to be a negative prognostic factor with regard to clinical outcome ( Table 4 ). The prevalence of hypercalcemia (38.9%) in our study was similar to findings in previous reports, with hypercalcemia noted in 25%-50% of dogs with AGASACA. 3, 5, 6 The prognostic relevance of hypercalcemia in AGASACA is discordantly reported in the veterinary literature. 3, 5, 30 Multiple studies have found no statistical significance associated with hypercalcemia. 3, 5, 30 However, other studies have found hypercalcemia to be a negative prognostic factor associated with shorter survival. 4 It is possible that interactions exist between hypercalcemia and other prognostic variables, which may explain the presence of prognostic significance in the multivariate Cox analysis but not in the KM analysis.
Our study was a retrospective analysis of observational clinical data. Therefore, imbalance across the variables studied and the presence of missing data are to be expected because patient restaging was inconsistent and several patients were lost to follow-up. Thirteen dogs were censored in the PFS analysis (including both macroscopic and microscopic disease settings) and 7 dogs were censored in the OST analysis (including both macroscopic and microscopic disease settings) because of lack of follow-up data. Also, few dogs (n = 7) were included in PFS and OST analysis for dogs treated in the microscopic disease setting. Furthermore, dogs in our study often received multiple treatment modalities including surgery and chemotherapy, in addition to toceranib. Among patients treated by chemotherapy, a variety of drugs and protocols were used. Thus, it is difficult to compare differences and interactions among these various treatment protocols. A larger database may be required for more thorough analysis, which would demand a collaborative effort with other veterinary hospitals.
| CONCLUSIONS
A clinical benefit from toceranib treatment was observed in the majority of dogs in our study (69%). Of dogs that experienced clinical benefit, most experienced stabilization rather than regression of their disease. Toceranib treatment-associated OST and PFS were 434 and 313 days, respectively. Response to toceranib treatment was associated with both improved OST and PFS. These results support the clinical efficacy of toceranib in the treatment of dogs with AGASACA.
Prospective, controlled clinical trials are needed to further evaluate the efficacy of toceranib in comparison to other treatments for dogs with AGASACA.
